Mankind Pharma Limited (MANKIND.NS) stock analysis
In our weekly check, Mankind Pharma Limited is graded B (A to F). Of 24 checks on debt, profit, cash flow and trend: 17 pass, warnings: 4, red flags: 3.
About Mankind Pharma Limited
Mankind Pharma Limited is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in India, listed on NSE as MANKIND.NS.
What our checks show for MANKIND.NS
Red flags
- The gross margin fell by 9.6 points, to 58.7%: costs are rising faster than prices.
- Profits not backed by cash
- Pay in shares equals 0% of free cash flow: it dilutes shareholders.
Warning signs
- The net margin fell by 3.8 points over 5 years, to 14.6%: the company keeps less of each sale as profit.
- Free cash flow is only 0% of revenue.
- The price is 45.9 times earnings (P/E): the market already pays for a lot of future growth.
- The stock is still below its previous peak.
Strengths
- Net debt is only 1x a year of EBITDA: the balance sheet has room.
- Analysts expect earnings per share to grow about 20.3% a year over the next years.
- Analysts expect the net margin to improve by 3 points from today's 14.6%.
- Revenue grew 20.7% a year over the last 3 years.
- Earnings per share grew 19.3% a year over the last 3 years.
- Net profit grew 20.5% a year over the last 3 years.
Similar companies
AUROPHARMA.NS · CIPLA.BO · DRREDDY.NS · LUPIN.NS · ZYDUSLIFE.NS · LAURUSLABS.NS
Questions
What grade does Mankind Pharma Limited (MANKIND.NS) have?
In our weekly check, Mankind Pharma Limited is graded B (A to F). Of 24 checks on debt, profit, cash flow and trend: 17 pass, warnings: 4, red flags: 3. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of MANKIND.NS stock?
This week's biggest flags for Mankind Pharma Limited: Gross margin falling, Profits not backed by cash, Heavy stock pay. In total 7 of 24 checks show a warning or a red flag.
What does Mankind Pharma Limited do?
Mankind Pharma Limited is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in India, listed on NSE as MANKIND.NS.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-10-31
Open the full analysis